SCHEDULE: HarbourVest Discloses 2.7% Stake in CAMP4 Therapeutics
Beneficial Ownership Report
HarbourVest Partners and affiliated entities reported a 2.7% beneficial ownership stake in CAMP4 Therapeutics Corporation, totaling 1,271,948 shares.
Summary
- HarbourVest Partners L.P., HarbourVest Partners, LLC, SMRS-TOPE LLC, and HVST-TOPE LLC collectively reported beneficial ownership of 1,271,948 shares of CAMP4 Therapeutics Corporation's common stock.
- This ownership represents 2.7% of the total class of securities outstanding.
- The percentage is calculated based on 46,842,126 shares of common stock outstanding, which includes 26,681,053 shares issued and sold to investors as reported in an 8-K on September 10, 2025, and 20,161,073 shares outstanding as of August 5, 2025, from a 10-Q filing.
- SMRS-TOPE LLC holds the shares directly and has sole voting and dispositive power over 1,271,948 shares.
- HarbourVest Partners, LLC, HarbourVest Partners L.P., and HVST-TOPE LLC may be deemed to have shared voting and dispositive power over these shares due to their managerial relationships with SMRS-TOPE LLC, but they disclaim beneficial ownership.
- The principal business office for all reporting persons is One Lincoln Street, Suite 1700, Boston, MA 02111.
Sentiment
Score: 5
Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G Amendment No. 1) and does not contain information that inherently indicates positive or negative sentiment. It is a factual report of an institutional investor's stake.
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a routine disclosure of institutional ownership, common in the biotechnology or pharmaceutical sector where venture capital and private equity firms often hold stakes in emerging companies. It reflects a passive investment position by HarbourVest Partners and its affiliates in CAMP4 Therapeutics Corporation.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership structure and the stake held by a significant institutional investor, HarbourVest Partners and its affiliates.
Key Dates
| Date | Description |
|---|---|
| August 5, 2025 | Date of common stock outstanding reported in the Issuer's Quarterly Report on Form 10-Q. |
| August 14, 2025 | Date of filing of the Issuer's Quarterly Report on Form 10-Q. |
| September 2025 | Date of the Joint Filing Agreement between reporting persons. |
| September 10, 2025 | Date of filing of the Issuer's Current Report on Form 8-K, reporting issuance and sale of shares to investors. |
| September 30, 2025 | Date of event which requires the filing of this statement. |
| October 1, 2025 | Signature date of the Schedule 13G Amendment No. 1 filing. |
Keywords
CAMP4 Therapeutics, HarbourVest Partners, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.